Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Identification of factors driving differences in cost effectiveness of first-line pharmacological therapy for uncomplicated hypertension.

Klarenbach SW, McAlister FA, Johansen H, Tu K, Hazel M, Walker R, Zarnke KB, Campbell NR; Canadian Hypertension Education Program..

Can J Cardiol. 2010 May;26(5):e158-63. Review.

2.

Patterns of prescription antihypertensive drug utilization and adherence to treatment guidelines in the city of Novi Sad.

Tomas A, Tomić Z, Milijasević B, Ban M, Horvat O, Vukmirović S, Sabo A.

Vojnosanit Pregl. 2016 Jun;73(6):531-7.

PMID:
27498444
3.

Cost-effectiveness analysis of guidelines for antihypertensive care in Finland.

Booth N, Jula A, Aronen P, Kaila M, Klaukka T, Kukkonen-Harjula K, Reunanen A, Rissanen P, Sintonen H, Mäkelä M.

BMC Health Serv Res. 2007 Oct 24;7:172.

4.

An economic evaluation of the 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of mild-to-moderate hypertension in Greece.

Stafilas PC, Sarafidis PA, Lasaridis AN, Aletras VH, Niakas DA.

Am J Hypertens. 2005 Sep;18(9 Pt 1):1233-40; discussion 1241-2.

PMID:
16182115
6.

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.

Forbes C, Shirran L, Bagnall AM, Duffy S, ter Riet G.

Health Technol Assess. 2001;5(28):1-110. Review.

7.

Cost-effectiveness of hypertension therapy according to 2014 guidelines.

Moran AE, Odden MC, Thanataveerat A, Tzong KY, Rasmussen PW, Guzman D, Williams L, Bibbins-Domingo K, Coxson PG, Goldman L.

N Engl J Med. 2015 Jan 29;372(5):447-55. doi: 10.1056/NEJMsa1406751. Erratum in: N Engl J Med. 2015 Apr 23;372(17):1677.

9.

Improving cost-effectiveness of hypertension management at a community health centre.

Edwards PR, Lunt DW, Fehrsen GS, Lombard CJ, Steyn K.

S Afr Med J. 1998 May;88(5):549-54.

PMID:
9638122
10.
11.

Pharmacoeconomics of hypertension control: basic principles of economic evaluation.

Wilson TW, Chockalingam A, Quest DW.

J Hum Hypertens. 1996 Feb;10 Suppl 2:S19-22.

PMID:
8868039
13.
14.
15.
16.

Effectiveness, safety and cost of drug substitution in hypertension.

Johnston A, Stafylas P, Stergiou GS.

Br J Clin Pharmacol. 2010 Sep;70(3):320-34. doi: 10.1111/j.1365-2125.2010.03681.x.

17.

Cost-effective therapy for hypertension.

Barrie W.

West J Med. 1996 Apr;164(4):303-9. Review.

18.

An economic evaluation of the JNC hypertension guidelines using data from a randomized controlled trial. Joint National Committee.

Ramsey SD, Neil N, Sullivan SD, Perfetto E.

J Am Board Fam Pract. 1999 Mar-Apr;12(2):105-14.

PMID:
10220232
19.

Telemonitoring and self-management in the control of hypertension (TASMINH2): a cost-effectiveness analysis.

Kaambwa B, Bryan S, Jowett S, Mant J, Bray EP, Hobbs FD, Holder R, Jones MI, Little P, Williams B, McManus RJ.

Eur J Prev Cardiol. 2014 Dec;21(12):1517-30. doi: 10.1177/2047487313501886.

PMID:
23990660
20.

Hypertension Improvement Project (HIP): study protocol and implementation challenges.

Dolor RJ, Yancy WS Jr, Owen WF, Matchar DB, Samsa GP, Pollak KI, Lin PH, Ard JD, Prempeh M, McGuire HL, Batch BC, Fan W, Svetkey LP.

Trials. 2009 Feb 26;10:13. doi: 10.1186/1745-6215-10-13.

Supplemental Content

Support Center